Ligand Pharmaceuticals | LGND - Betriebsergebnis

Aktienkurs
231.27
Täglich Wechseln
2.79 1.22%
Monatlich
13.06%
Jährlich
114.00%
Q2 Prognose
226.72




Betriebsergebnis Veränderung Datum
Agenus USD 14.4M 19.26M 2025-12
Amgen USD 3.96B 464M 2025-12
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD 40.81M 3.3M 2025-12
Baxter International USD -214.2M 415.4M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Enviri Corporation USD -35.28M 61.58M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Intrexon USD -60.84M 26.62M 2024-06
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Ligand Pharmaceuticals USD 158.89M 149.17M 2025-09
MacroGenics USD -12.1M 30.74M 2025-12
Merck USD 6.24B 318M 2025-12
Pacira USD 3.19M 9.96M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Veracyte USD 24.63M 1.52M 2025-12